January 12, 2024
Bulletin interne de l'Institut Pasteur
Sensorion Announces Partnership with the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders has been Extended for Five Years
The framework extension agreement underlines the successful collaboration between Sensorion and the Institut Pasteur, involving the Hearing Institute, a research center of the Institut Pasteur, focused on the development of gene therapy programs
Two gene therapy development programs are currently being conducted under this agreement, including SENS-501 (OTOF-GT) and GJB2-GT. Sensorion submitted a Clinical Trial Application in July 2023 for SENS-501 to initiate a Phase 1/2 clinical trial in the United Kingdom (UK) and in the European Union (EU).